MCID: MRK001
MIFTS: 50

Merkel Cell Carcinoma

Categories: Rare diseases, Skin diseases, Endocrine diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Merkel Cell Carcinoma

MalaCards integrated aliases for Merkel Cell Carcinoma:

Name: Merkel Cell Carcinoma 12 50 56 29 14 69
Cutaneous Neuroendocrine Carcinoma 50 56
Trabecular Adenocarcinoma 12 69
Carcinoma, Merkel Cell 50
Carcinoma Merkel Cell 52
Trabecular Carcinoma 12
Merkel Cell Cancer 50
Merkle Tumors 50
Mcc 56

Characteristics:

Orphanet epidemiological data:

56
cutaneous neuroendocrine carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Europe),1-9/100000 (Australia); Age of onset: Adult; Age of death: elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:3965
NCIt 47 C4068
SNOMED-CT 64 29792007
Orphanet 56 ORPHA79140
UMLS via Orphanet 70 C0007129
ICD10 via Orphanet 34 C44.3 C44.6 C44.7
UMLS 69 C0302182

Summaries for Merkel Cell Carcinoma

NIH Rare Diseases : 50 merkel cell carcinoma (mcc) is a rare, aggressive skin cancer. it usually develops as a single, painless, bump on sun-exposed skin. the bump may be skin-colored or red-violet, and tends to grow rapidly over weeks to months. it may spread quickly to surrounding tissues, nearby lymph nodes, or more distant parts of the body. factors associated with developing mcc include increasing age, fair skin, a history of extensive sun exposure, chronic immune suppression, and the merkel cell polyomavirus. this virus has been detected in about 80% of people with mcc. treatment may include surgery, radiation therapy, and/or chemotherapy. treatment options and prognosis depend on the location(s) and size of the cancer, whether it has just been diagnosed or has come back (recurred), and how deeply it has grown into the skin. last updated: 3/9/2017

MalaCards based summary : Merkel Cell Carcinoma, also known as cutaneous neuroendocrine carcinoma, is related to glomus tumor and pheochromocytoma. An important gene associated with Merkel Cell Carcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are NF-kappaB Signaling and Neuroscience. The drugs Antibodies and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are behavior/neurological and mortality/aging

Wikipedia : 72 Merkel-cell carcinoma (MCC) is a rare and highly aggressive skin cancer, which, in most cases, is caused... more...

Related Diseases for Merkel Cell Carcinoma

Diseases related to Merkel Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 317)
id Related Disease Score Top Affiliating Genes
1 glomus tumor 29.9 ENO2 KIT NCAM1 SYP
2 pheochromocytoma 29.7 CHGA ENO2 SST SYP
3 neuroblastoma 29.2 ENO2 KIT NCAM1 SYP TP53
4 penile cancer 11.0
5 periosteal osteogenic sarcoma 10.9 KRT20 NKX2-1
6 malignant ovarian mixed epithelial neoplasm 10.9 CHGA SYP
7 sensory system cancer 10.9 CHGA KRT20
8 lung occult small cell carcinoma 10.9 CHGA KRT20
9 spinal cord ependymoma 10.9 CHGA SYP
10 fibroepithelial polyp of urethra 10.9 CHGA KRT20
11 signet ring cell intrahepatic cholangiocarcinoma 10.8 CHGA SYP
12 paranasal sinus cancer 10.8 ENO2 SYP
13 basophilic carcinoma 10.8 CHGA SYP
14 neurogenic thoracic outlet syndrome 10.8 CHGA SYP
15 clear cell squamous cell skin carcinoma 10.8 KIT KRT20
16 familial renal oncocytoma 10.8 ENO2 KRT20
17 aicardi-goutieres syndrome 10.8 CHGA SYP
18 supratentorial primitive neuroectodermal tumor 10.8 CHGA ENO2
19 rhinosporidiosis 10.8 KRT20 MUC1
20 diffuse infiltrative lymphocytosis syndrome 10.8 CHGA SYP
21 invasive malignant thymoma 10.8 KIT SYP
22 dedifferentiated liposarcoma 10.8 KIT MUC1
23 meningitis and encephalitis 10.7 ENO2 MUC1
24 small intestine leiomyoma 10.7 KRT20 TP53
25 intrahepatic bile duct adenoma 10.7 KRT20 TP53
26 extrahepatic bile duct adenoma 10.7 KRT20 TP53
27 cauda equina intradural extramedullary astrocytoma 10.7 ENO2 SYP
28 testicular trophoblastic tumor 10.7 KRT20 MUC1
29 arteriosclerosis obliterans 10.7 ENO2 NCAM1
30 myoma 10.7 ENO2 MUC1
31 retroperitoneal leiomyosarcoma 10.7 ENO2 KIT
32 mannose-binding lectin protein deficiency 10.7 KIT MUC1
33 mucinous adenocarcinoma 10.7 KIT KRT20
34 intraductal breast myoepitheliosis 10.7 CHGA TP53
35 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.7 SYP TP53
36 esophagus adenocarcinoma 10.7 CHGA NKX2-1 SYP
37 verruciform xanthoma of skin 10.7 ENO2 NCAM1
38 parietal lobe neoplasm 10.7 CHGA ENO2
39 pyoderma 10.7 CHGA MUC1
40 morbid obesity 10.7 ENO2 MUC1
41 iris spindle cell melanoma 10.7 MUC1 NCAM1
42 hypogonadotropic hypogonadism without anosmia, x-linked 10.7 NCAM1 SYP
43 central nervous system hematologic cancer 10.7 CHGA NKX2-1 SYP
44 epithelioid sarcoma 10.7 MUC1 SYP
45 fallopian tube squamous cell carcinoma 10.7 KIT TP53
46 breast apocrine carcinoma in situ 10.6 SST SYP
47 testicular malignant germ cell cancer 10.6 ENO2 NCAM1
48 thymus large cell carcinoma 10.6 ENO2 SYP
49 primary syphilis 10.6 CHGA SST
50 myoepithelial carcinoma 10.6 KIT KRT20 NKX2-1

Graphical network of the top 20 diseases related to Merkel Cell Carcinoma:



Diseases related to Merkel Cell Carcinoma

Symptoms & Phenotypes for Merkel Cell Carcinoma

MGI Mouse Phenotypes related to Merkel Cell Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 MAP2 NCAM1 NKX2-1 PAX5 SST SYP
2 mortality/aging MP:0010768 9.7 ATOH1 CD274 CHGA KIT KRT8 MAP2
3 nervous system MP:0003631 9.32 ATOH1 ENO2 KIT MAP2 NCAM1 NKX2-1

Drugs & Therapeutics for Merkel Cell Carcinoma

Drugs for Merkel Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 3,Phase 2,Phase 1
2 Immunoglobulins Phase 3,Phase 2,Phase 1
3
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
4
Somatostatin Approved Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
5
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
7
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
8 lanreotide Approved Phase 2 108736-35-2
9
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
10
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
11
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
12
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
13
nivolumab Approved Phase 2,Phase 1 946414-94-4
14
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
15
Daratumumab Approved Phase 1, Phase 2 945721-28-8
16
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
17
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
18
Etoposide Approved Phase 2 33419-42-0 36462
19
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
20
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
22
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
23
Glutamic Acid Approved, Nutraceutical Phase 1, Phase 2 56-86-0 33032
24
Camptothecin Experimental Phase 2 7689-03-4
25
Tremelimumab Investigational Phase 1, Phase 2 745013-59-6
26 Albumin-Bound Paclitaxel Phase 2,Phase 1
27 Analgesics Phase 2,Phase 1
28 Analgesics, Non-Narcotic Phase 2,Phase 1
29 Antibodies, Monoclonal Phase 2,Phase 1
30 Antimitotic Agents Phase 2,Phase 1
31 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
32 Interleukin-2 Phase 2,Phase 1
33 Peripheral Nervous System Agents Phase 2,Phase 1
34 Hormone Antagonists Phase 2,Phase 1
35 Hormones Phase 2,Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
37 Adjuvants, Immunologic Phase 2
38 Angiogenesis Inhibitors Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 2,Phase 1
40 Interleukin-12 Phase 2
41 Vaccines Phase 2,Phase 1
42 Alkylating Agents Phase 2,Phase 1
43 Antimetabolites Phase 2,Phase 1
44 Antimetabolites, Antineoplastic Phase 2,Phase 1
45 Antirheumatic Agents Phase 2,Phase 1
46 Dermatologic Agents Phase 2
47 Folic Acid Antagonists Phase 2
48 Immunosuppressive Agents Phase 2,Phase 1
49 Nucleic Acid Synthesis Inhibitors Phase 2
50 Vitamin B Complex Phase 2

Interventional clinical trials:

(show top 50) (show all 57)

id Name Status NCT ID Phase Drugs
1 Adjuvant Avelumab in Merkel Cell Cancer Not yet recruiting NCT03271372 Phase 3 Avelumab
2 F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma Unknown status NCT02054884 Phase 2 Arm A: F16IL2 in combination with paclitaxel;Arm B: Paclitaxel
3 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Unknown status NCT01237457 Phase 2 177Lu-DOTATATE
4 IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer Completed NCT01440816 Phase 2
5 Oblimersen in Treating Patients With Merkel Cell Carcinoma Completed NCT00079131 Phase 2
6 S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer Completed NCT00003549 Phase 2 CMF regimen;cyclophosphamide;fluorouracil;methotrexate
7 S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer Completed NCT00068783 Phase 2 imatinib mesylate
8 Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues Completed NCT02351128 Phase 2 Lanreotide
9 Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors Completed NCT00004922 Phase 2 irinotecan hydrochloride
10 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
11 Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation Recruiting NCT02196961 Phase 2 Ipilimumab;Nivolumab
12 MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma Recruiting NCT02514824 Phase 1, Phase 2 MLN0128
13 Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) Recruiting NCT02155647 Phase 2 Avelumab
14 A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors Recruiting NCT02819843 Phase 2 TALIMOGENE LAHERPAREPVEC (TVEC)
15 Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma Recruiting NCT03071406 Phase 2 Nivolumab;Ipilimumab
16 Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Recruiting NCT02978625 Phase 2
17 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma Recruiting NCT02501473 Phase 1, Phase 2 G100;Pembrolizumab
18 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors Recruiting NCT02488759 Phase 1, Phase 2 Nivolumab;Ipilimumab;BMS-986016;Daratumumab
19 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Recruiting NCT02936323 Phase 1, Phase 2 PEN-221
20 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers Recruiting NCT02643303 Phase 1, Phase 2 Durvalumab;Tremelimumab;Poly ICLC
21 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Recruiting NCT03126110 Phase 1, Phase 2 INCAGN01876;Nivolumab;Ipilimumab
22 Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab;Bevacizumab
23 Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma Active, not recruiting NCT02036476 Phase 2 Cabozantinib
24 QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC) Active, not recruiting NCT02465957 Phase 2
25 Merkel Positron Emission Tomography (PET) Protocol Active, not recruiting NCT01013779 Phase 2 Carboplatin;Etoposide
26 Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer Active, not recruiting NCT02267603 Phase 2
27 QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy Not yet recruiting NCT03167164 Phase 1, Phase 2 Capecitabine;Cisplatin;Cyclophosphamide;5-fluorouracil;Leucovorin;nab-Paclitaxel;omega-3-acid ethyl esters
28 Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer Not yet recruiting NCT03304639 Phase 2
29 Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma Not yet recruiting NCT03322384 Phase 1, Phase 2 epacadostat;SD-101
30 A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies Not yet recruiting NCT03241173 Phase 1, Phase 2 INCAGN01949;Nivolumab;Ipilimumab
31 INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Not yet recruiting NCT03277352 Phase 1, Phase 2 INCAGN01876;Epacadostat;Pembrolizumab
32 Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Suspended NCT02584829 Phase 1, Phase 2 Avelumab
33 Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma Terminated NCT01758458 Phase 1, Phase 2
34 Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma Withdrawn NCT01913691 Phase 2 Ipilimumab
35 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
36 A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel C Completed NCT01652547 Phase 1 Pasireotide sub-cutaneous formulation;Pasireotide lon acting release formulation
37 BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00346385 Phase 1 BB-10901
38 Endoscopic Treatment of Inoperable Colorectal Cancer With the EndoVe System Completed NCT01172860 Phase 1
39 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
40 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
41 89Zr-Df-IAB22M2C PET/CT in Patients With Selected, Metastatic Solid Malignancies or Hodgkin's Lymphoma Recruiting NCT03107663 Phase 1 89Zr-Df-IAB22M2C Infusion
42 Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Recruiting NCT02890368 Phase 1 TTI-621
43 Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers Recruiting NCT03212404 Phase 1 CK-301
44 A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting NCT03071757 Phase 1 ABBV-368;Nivolumab
45 A Study of ABBV-181 in Participants With Advanced Solid Tumors Recruiting NCT03000257 Phase 1 ABBV-181;Rovalpituzumab Tesirine
46 A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma Active, not recruiting NCT02035657 Phase 1
47 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1 everolimus;vatalanib
48 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
49 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
50 The Impact of Total Body Skin Examination on Skin Cancer Detection Completed NCT00765193

Search NIH Clinical Center for Merkel Cell Carcinoma

Genetic Tests for Merkel Cell Carcinoma

Genetic tests related to Merkel Cell Carcinoma:

id Genetic test Affiliating Genes
1 Merkel Cell Carcinoma 29

Anatomical Context for Merkel Cell Carcinoma

MalaCards organs/tissues related to Merkel Cell Carcinoma:

39
Skin, Lymph Node, Lung, T Cells, Pancreas, Thyroid, Kidney

Publications for Merkel Cell Carcinoma

Articles related to Merkel Cell Carcinoma:

(show top 50) (show all 785)
id Title Authors Year
1
Tropomyosin Receptor Kinase A Expression on Merkel Cell Carcinoma Cells. ( 28793172 )
2017
2
Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. ( 28916903 )
2017
3
Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience. ( 28802661 )
2017
4
Subacute Cerebellar Degeneration due to a Paraneoplastic Phenomenon Associated with Metastatic Merkel Cell Carcinoma: A Case Report. ( 28878663 )
2017
5
Avelumab for the treatment of metastatic Merkel cell carcinoma. ( 28837181 )
2017
6
Sentinel lymph node biopsy in periocular merkel cell carcinoma: a case report. ( 28931417 )
2017
7
Merkel cell polyomavirus and Merkel cell carcinoma. ( 28893943 )
2017
8
Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab. ( 28761962 )
2017
9
A population-based cohort study of the influence of socioeconomic factors and race on survival in Merkel cell carcinoma. ( 27986144 )
2017
10
Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma. ( 28049147 )
2017
11
Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. ( 27984768 )
2017
12
The diagnostic utility of Merkel cell polyomavirus immunohistochemistry in a fine needle aspirate of metastatic Merkel cell carcinoma of unknown primary to the pancreas. ( 28802095 )
2017
13
Merkel cell carcinoma: Do Australians have a more aggressive variant and a worse outcome? ( 28804895 )
2017
14
Eyelid Merkel cell carcinoma in a patient treated with golimumab. ( 28841334 )
2017
15
Merkel Cell Carcinoma of the Head and Neck: Recommendations for Diagnostics and Treatment. ( 28762116 )
2017
16
A thoracic vertebral localization of a metastasized cutaneous Merkel cell carcinoma: Case report and review of literature. ( 28868202 )
2017
17
Merkel Cell Carcinoma with Distant Metastasis to the Clivus Causing Symptoms Mimicking Tolosa-Hunt Syndrome: A Case Report and Literature Review. ( 28868044 )
2017
18
Phospho-STAT5B Expression Is a Prognostic Marker for Merkel Cell Carcinoma. ( 28476799 )
2017
19
Merkel cell carcinoma cardiac metastasis causing cardiac tamponade. ( 28951515 )
2017
20
Expression of Merkelcell polyomavirus (MCPyV) large T-antigen in Merkel cell carcinoma lymph node metastases predicts poor outcome. ( 28763479 )
2017
21
History of chronic inflammatory disorders increases the risk of Merkel cell carcinoma, but does not correlate with Merkel cell polyomavirus infection. ( 27978533 )
2017
22
Merkel Cell Carcinoma. ( 28920480 )
2017
23
Update on Merkel Cell Carcinoma. ( 28802497 )
2017
24
Advances in Merkel cell carcinoma from a pathologist's perspective. ( 28844339 )
2017
25
Checkpoint blockade for metastatic melanoma and Merkel cell carcinoma in HIV-positive patients. ( 28950303 )
2017
26
Skin ultrasound features of Merkel cell carcinoma. ( 28045198 )
2017
27
A 76 year old male with an unusual presentation of merkel cell carcinoma. ( 27161548 )
2016
28
Histological Features, p53, c-Kit, and Poliomavirus Status and Impact on Survival in Merkel Cell Carcinoma Patients. ( 27442046 )
2016
29
Rapidly Fatal Dissemination of Merkel Cell Carcinoma in a Patient Treated with Alemtuzumab for Chronic Lymphocytic Leukemia. ( 27509643 )
2016
30
Update on Merkel Cell Carcinoma: Epidemiology, Etiopathogenesis, Clinical Features, Diagnosis, and Staging. ( 27770997 )
2016
31
Sentinel lymph node biopsy and survival in Merkel cell carcinoma: A 10 year review. ( 27544843 )
2016
32
Squamous Cell Carcinoma In Situ Overlying Merkel Cell Carcinoma. ( 27207346 )
2016
33
The value of sentinel lymph node biopsy in Merkel cell carcinoma: reply from the authors. ( 27476497 )
2016
34
Metastatic Merkel cell carcinoma of the face. ( 27212280 )
2016
35
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. ( 27592805 )
2016
36
A high neutrophil-to-lymphocyte ratio as a potential marker of mortality in patients with Merkel cell carcinoma: A retrospective study. ( 27544490 )
2016
37
Single-centre experience of primary cutaneous Merkel cell carcinoma of the head and neck between 1996 and 2014. ( 27156234 )
2016
38
Roles for miR-375 in Neuroendocrine Differentiation and Tumor Suppression via Notch Pathway Suppression in Merkel Cell Carcinoma. ( 26877261 )
2016
39
Secondary Merkel Cell Carcinoma Arising From a Graft Donor Site. ( 27777334 )
2016
40
RB1 is the crucial target of the Merkel cell polyomavirus Large T antigen in Merkel cell carcinoma cells. ( 27121059 )
2016
41
A pilot study of SPECT/CT-based mixed-reality navigation towards the sentinel node in patients with melanoma or Merkel cell carcinoma of a lower extremity. ( 27076206 )
2016
42
Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma? ( 27592804 )
2016
43
Recurrent Merkel cell carcinoma of the testis with unknown primary site: a case report. ( 27814751 )
2016
44
Presence of the Merkel cell polyomavirus in Merkel cell carcinoma combined with squamous cell carcinoma in a patient with chronic arsenism. ( 27774637 )
2016
45
Metastatic Merkel cell carcinoma response to nivolumab. ( 27879975 )
2016
46
Merkel Cell Carcinoma of the Eyelid. ( 27664912 )
2016
47
Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenia in a patient with Merkel cell carcinoma and voltage-gated calcium channel antibodies. ( 28006860 )
2016
48
Revisiting PAX-8's Labeling of Merkel Cell Carcinoma. ( 28002100 )
2016
49
Epidemiological trends in Merkel cell carcinoma in southern France: a registry-based study. ( 27515470 )
2016
50
Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. ( 27177440 )
2016

Variations for Merkel Cell Carcinoma

Cosmic variations for Merkel Cell Carcinoma:

9 (show all 15)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10660 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.818G>A p.R273H 19
2 COSM11491 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.743G>C p.R248P 19
3 COSM10656 TP53 skin,NS,carcinoma,Merkel cell carcinoma c.742C>T p.R248W 19
4 COSM1735722 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.298G>A p.G100R 19
5 COSM1735721 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.297G>A p.W99* 19
6 COSM214151 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.585G>A p.W195* 19
7 COSM1731707 RB1 skin,NS,carcinoma,Merkel cell carcinoma c.1789C>T p.Q597* 19
8 COSM5316 PTEN skin,NS,carcinoma,Merkel cell carcinoma c.439A>T p.K147* 19
9 COSM766 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1636C>A p.Q546K 19
10 COSM27133 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1633G>C p.E545Q 19
11 COSM760 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.1624G>A p.E542K 19
12 COSM776 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.3140A>T p.H1047L 19
13 COSM249774 PIK3CA skin,NS,carcinoma,Merkel cell carcinoma c.56G>A p.R19K 19
14 COSM29052 PTCH1 skin,back,carcinoma,NS c.724C>T p.Q242* 16
15 COSM763 PIK3CA skin,back,carcinoma,NS c.1633G>A p.E545K 16

Copy number variations for Merkel Cell Carcinoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 32219 1 34600000 44100000 Amplification MYCL1 Merkel cell carcinoma
2 77110 13 40100000 73300000 Deletion Merkel cell carcinoma
3 200959 5 63200000 102800000 Deletion Merkel cell carcinoma

Expression for Merkel Cell Carcinoma

Search GEO for disease gene expression data for Merkel Cell Carcinoma.

Pathways for Merkel Cell Carcinoma

Pathways related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.95 CD274 KIT NCAM1 PAX5
2 11.53 ENO2 MAP2 NCAM1 NKX2-1 SYP
3 11.03 MAP2 NCAM1 SYP

GO Terms for Merkel Cell Carcinoma

Biological processes related to Merkel Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 MUC1 TP53
2 mast cell degranulation GO:0043303 9.16 CHGA KIT
3 mast cell chemotaxis GO:0002551 8.96 CHGA KIT
4 mast cell cytokine production GO:0032762 8.62 CHGA KIT

Sources for Merkel Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....